Summary Epidermal growth factor receptor (EGFR) gene copy number (GCN) increase is associated with a favorable anti-EGFR antibody treatment response in RAS wild-type metastatic colorectal cancer. However, there are limited and comparative data regarding the EGFR GCN in primary colorectal cancer tumors and corresponding metastases or the effect of anti-EGFR antibody treatment on EGFR GCN in recurrent disease. In addition, little is known about the potential EGFR GCN changes during anti-EGFR therapy in comparison with other treatment regimens. EGFR GCN was analyzed by EGFR immunohistochemistry-guided silver in situ hybridization in primary and corresponding recurrent local or metastatic tumors from 80 colorectal cancer patients. GCN levels were compared between KRAS wild-type patients having received anti-EGFR therapy and patients having received other forms of treatment after primary surgery. The EGFR GCN decrease between primary and recurrent tumors was more pronounced among the anti-EGFR-treated patients than among patients not treated with anti-EGFR therapy (P = .047). None of the patients experiencing an EGFR GCN increase of at least 1.0 between the primary and recurrent tumors were treated with anti-EGFR antibodies. When including only patients with distant metastases, an EGFR GCN decrease of at least 1.0 was more common among the anti-EGFR-treated patients than among patients not treated with anti- EGFR therapy (P = .028). Our results suggest that anti-EGFR antibody treatment is associated with EGFR GCN decrease between the primary and recurrent colorectal adenocarcinomas, whereas no GCN change is observed among patients receiving other forms of treatment after primary surgery.
Introduction
Epidermal growth factor receptor (EGFR) is a transmembrane receptor tyrosine kinase that can initiate several intracellular signaling pathways contributing to cancer cell proliferation, inhibition of apoptosis, invasion, metastasis, and stimulation of neovascularization. The main regulatory routes of EGFR are the RAS-RAF-MAPK and the PI3K-Akt signaling pathways [1] . The central role of EGFR in cancer progression is used in the treatment of RAS wild-type metastatic colorectal cancer (CRC) by EGFR-targeting monoclonal antibodies cetuximab and panitumumab [2] [3] [4] [5] [6] [7] . In addition to RAS status, an EGFR gene copy number (GCN) of at least 4.0 in the primary tumor has been associated with a favorable anti-EGFR antibody treatment response in patients with RAS wild-type CRC [8] [9] [10] . However, there are limited comparative data regarding the EGFR GCN in the primary CRC tumors and the corresponding metastases, and few studies have examined the effect of anti-EGFR antibody treatment on the EGFR GCN in the metastatic tumors. Here, we analyzed the concordance of EGFR GCN between primary and recurrent CRC tumors in patients treated with anti-EGFR therapy in comparison with patients receiving other forms of treatment after primary surgery.
Materials and methods

Patients and clinical tumor material
The study population in this retrospective study consists of 80 patients treated for CRC at the Turku University Hospital (n = 66) and Central Finland Central Hospital (n = 14) between 2000 and 2015. Three of the Turku patients had their liver metastasis resections performed at the Helsinki University Hospital. The inclusion criteria were diagnosis of adenocarcinoma in the colon or rectum and the availability of both primary and recurrent tumor material for the study purposes. The recurrent tumors were either local recurrences or distant metastases. The median age of the patients at the time of diagnosis was 66 years (range, 34-86 years). Most of the patients (58.8%) had KRAS wild-type tumors. The KRAS mutation testing was performed in primary tumors for 76 patients and in recurrent tumors for 3 patients. For 1 patient, both the primary and recurrent tumors were tested for clinical purposes.
Altogether 24 of 80 patients were treated with anti-EGFR therapy. Of those, the relationship between EGFR GCN change and anti-EGFR antibody treatment was analyzed in KRAS wild-type CRC patients whose primary tumor samples were obtained before and recurrent tumor samples after the administration of anti-EGFR therapy (n = 14). The patients received cetuximab or panitumumab either as single therapy or in combination with irinotecan. The EGFR GCN of their tumor samples was compared with the samples of patients receiving adjuvant chemotherapy or no adjuvant therapy after primary surgery. One patient was excluded from the analyses because the sample taken before anti-EGFR treatment was obtained from the metastatic site. In addition, 1 anti-EGFRtreated patient was excluded from the analyses regarding antibody therapy because the primary tumor was KRAS mutated.
The response to anti-EGFR antibody treatment was evaluated in 13 patients receiving antibodies before the sample was obtained from the recurrent tumor. The evaluation was performed by computed tomography or magnetic resonance imaging according to the Response Evaluation Criteria in Solid Tumors [11] . The median follow-up time of all the patients was 97 months (range, 8-174 months). At the end of the follow-up period, 28% (22/80) of the patients were alive. The reporting of the study has been performed in compliance with the current recommendations [12] . The patient and tumor characteristics are presented in more detail in Table 1 .
The study was conducted in accordance with the Declaration of Helsinki and the Finnish legislation for the use of archived tissue specimens and associated clinical information. The clinical data were retrieved, and the histologic samples were collected and analyzed with the endorsement of the National Authority for Medico-Legal Affairs and the institutional review board of the Hospital District of Southwest Finland. Oral or written informed consent was not obtained because most of the patients included in this study had died of their disease. The need for informed consent from participants was waived by the National Authority for Medico-Legal Affairs.
KRAS mutation testing
For all patients, KRAS point mutations within codons 12, 13, and 61 were detected from formalin-fixed, paraffin-embedded (FFPE) tissue material containing at least 30% of CRC cells. For 60 (75%) patients, the KRAS gene was analyzed with pyrosequencing technique using the IVD marked Qiagen TheraScreen KRAS Pyro kit (catalog no. 971460; Qiagen GmbH, Hilden, Germany). The testing was performed according to the protocol provided by the manufacturer. Shortly, 10-μm-thick FFPE tissue slices (5-10 per sample) were collected to a microsentrifuge tube, and the DNA 
EGFR immunohistochemistry and silver in situ hybridization
The EGFR immunohistochemistry (IHC) staining and EGFR GCN analysis procedures have been described previously [8] [9] [10] . Briefly, EGFR IHC staining was performed on 3-μm sections with a monoclonal antibody against the internal domain of EGFR (Ventana Medical Systems/Roche Diagnostics, Tucson, AZ; clone 5B7). The stainings were executed with BenchMark XT (Ventana/Roche) using ultraView Universal DAB Detection Kit (Ventana/Roche). EGFR gene was detected from 5-μm sections with EGFR DNA Probe (Ventana/ Roche), and silver in situ hybridization (SISH) was performed with the BenchMark XT using ultraVIEW SISH Detection Kit (Ventana/Roche). EGFR GCN was calculated as a mean value from 40 tumor cells from the areas of highest IHC reactivity in each tumor.
When calculating the EGFR GCN change between the primary and corresponding metastatic tumors, a cutoff value of 1.0 was used to signify a notable alteration in the GCN. In addition to the cutoff value of 1.0 for EGFR GCN change, we tested the cutoff value 4.0, which we have previously shown to predict anti-EGFR treatment response in metastatic CRC [8] . EGFR IHC and EGFR GCN were scored independently by 2 observers (J. S. and T. A., E. B., or M. L.) without knowledge of the clinical information. In cases of discordance, a consensus was made between the 2 observers. EGFR GCN could not be analyzed in one primary tumor because the hybridization reaction was too weak.
Statistical analyses
Statistical analyses were performed with IBM SPSS Statistics for Windows, version 24.0 (IBM Corporation, Armonk, NY). Frequency table data were analyzed with the Pearson χ 2 test or Fisher exact test for categorical variables. Tables of 2 × 2 were used to calculate odds ratios (ORs) and 95% confidence intervals (CIs) using the exact method. To compare the mean GCN in relation to categorical variables, nonparametric Mann-Whitney and Kruskal-Wallis tests were used because the EGFR GCN was not normally distributed. Pairwise concordance of EGFR GCN between primary and metastatic tumors was analyzed using a nonparametric paired-samples test (McNemar and Wilcoxon signed-rank test). KaplanMeier method with log-rank test and Cox proportional hazards regression model were used for univariate survival analysis. Disease-free survival was calculated from the time of diagnosis to the time of first recurrence, death of primary cancer, or the last follow-up date. Overall survival was calculated from the time of diagnosis to the time of death of any cause or the last follow-up date. All statistical tests were 2-sided, and P values less than .05 were considered statistically significant.
Results
EGFR GCN in the primary and recurrent tumors
Among the primary tumors (n = 78), the median EGFR GCN was 3.98, and in the recurrent tumors (n = 79), the median EGFR GCN was 3.80. The median change in EGFR GCN was −0.14 units during disease progression, which is equivalent to a relative median change of −4.1% between the corresponding primary and recurrent tumors. The EGFR GCNs between the primary and recurrent tumors were not significantly different in the whole study population. When using EGFR GCN 4.0 as a cutoff, the GCN status did not significantly change during disease progression. The EGFR SISH results are presented in Table 2 .
EGFR GCN decrease after anti-EGFR antibody therapy
EGFR GCN of the primary tumors did not differ between patients treated later with anti-EGFR therapy (n = 14) and patients receiving other forms of therapy (n = 63; MannWhitney U test, P = .588). Similarly, the EGFR GCN of the recurrent tumors did not differ between patients having received anti-EGFR therapy (n = 14) and patients not treated with anti-EGFR therapy (n = 64; Mann-Whitney U test, P = .123).
There was a significant decrease in EGFR GCN between the primary (mean, 5.55; median, 4.26) and recurrent tumors (mean, 3.92; median, 3.43) among the anti-EGFR-treated patients (Wilcoxon signed-rank test, P = .028) but not among patients not treated with anti-EGFR therapy. In addition, the relative GCN decrease was significantly more pronounced during anti-EGFR therapy than during other treatment regimens (Mann-Whitney U test, P = .047).
When EGFR GCN change of at least 1.0 was used as a cutoff value, GCN decrease or stable GCN was observed slightly more often among the anti-EGFR-treated patients than among patients not treated with anti-EGFR therapy (Fisher exact test, P = .050). None of the patients experienced GCN increase between the primary and recurrent tumors during anti-EGFR therapy. In contrast, EGFR GCN increased in 23.8% (15/63) of the patients during other treatment regimens. The association between EGFR GCN decrease and anti-EGFR therapy became more pronounced when including only patients with distant metastases in the analysis and using dichotomous classification (GCN increase versus decrease/no change; Fisher exact test, P = .028; relative risk, 1.38; 95% CI, 1.15-1.65).
With regard to the 4.0 cutoff value, discordant EGFR GCN was detected in 35.9% (28/78) of the primary-metastasis tumor Table 3 compares the EGFR GCN alterations between patients treated with anti-EGFR antibodies and patients receiving other treatment regimens after primary surgery. EGFR GCN decrease between a primary colorectal adenocarcinoma and the corresponding liver metastasis after anti-EGFR antibody treatment is demonstrated in the Figure. 
EGFR GCN in relation to the clinicopathological variables
Primary wild-type KRAS tumors had higher EGFR GCN (mean, 4.88; median, 4.20; range, 2.57-15.0) than did primary KRAS-mutated tumors (mean, 3.79; median, 3.50; range, 2.00-8.00; Mann-Whitney U test, P = .019). In KRAS wild-type tumors, EGFR GCN ≥ 4.0 was detected more often than in KRAS-mutated tumors (Fisher exact test, P = .021; OR, 3.29; 95% CI, 1.28-8.45).
EGFR GCN of the primary tumors was observed to be higher in patients with stage III disease (mean, 4.66; median, 4.25; range, 2.00-15.0) than in patients with stage I-II disease (mean, 3.96; median, 3.55; range, 2.50-10.0; Mann-Whitney U test, P = .024). Similarly, patients with stage III disease had more often EGFR GCN ≥ 4.0 than did patients with stage I-II disease (Fisher exact test, P = .037; OR, 2.84; 95% CI, 1.11-7.31). Particularly, patients with N1-2 lymph node status had higher EGFR GCN (mean, 4.79; median, 4.25; range, 2.00-15.0) than did patients with N0 (mean, 3.93; median, 3.50; range, 2.50-10.0; Mann-Whitney U test, P = .018). N1-2 lymph node status was also associated with EGFR GCN ≥ 4.0 (Fisher exact test, P = .039; OR, 2.91; 95% CI, 1.15-7.37).
No significant association was seen between EGFR GCN change and patient sex, age, the location of primary tumor (colon versus rectum or left-sided versus right-sided), the depth of tumor invasion, tumor differentiation grade, or recurrent tumor site (local versus distant). The results from selected clinicopathological analyses are shown in Table 4 .
Discussion
Anti-EGFR treatment is currently recommended for the treatment for patients with RAS wild-type metastatic CRC [6, 7] . We have previously shown that EGFR GCN, analyzed with SISH, is a promising predictive biomarker in these patients [8] [9] [10] . However, in previous studies, EGFR GCN analyses have mainly been performed on primary tumor tissue, and little is known about the potential effects of anti-EGFR therapy on EGFR GCN in recurrent disease [8] [9] [10] 13, 14] . In the present study, we have observed a decreasing trend in EGFR GCN among patients treated with anti-EGFR antibodies as compared with patients not receiving anti-EGFR therapy after primary surgery.
A few studies have investigated EGFR protein expression levels in primary and corresponding metastatic CRC tumors. However, data referring to EGFR GCN in metastatic tumors are limited, and few studies have compared EGFR GCN between primary and recurrent tumors in patients treated with anti-EGFR therapy. In these studies, discordance of EGFR GCN determined by fluorescent in situ hybridization has been reported in 5% to 13% of patients treated with anti-EGFR antibodies, but these analyses have not taken into account the KRAS status of the patients [15, 16] .
In a study by Molinari et al [17] , 33% (12/36) of the patients were treated with anti-EGFR therapy. However, 5 of them were KRAS mutated and thus nonresponders. In line with our findings, the EGFR fluorescent in situ hybridization pattern remained stable between the primary and metastatic tumors in all of the KRAS wild-type patients treated with anti-EGFR antibodies, whereas 5 of the 24 patients not treated with anti-EGFR antibodies showed GCN increase.
In the present study, a significant decrease in EGFR GCN was observed between the primary and recurrent tumors among the anti-EGFR-treated patients but not among patients receiving other treatment regimens after primary surgery. Notably, none of the patients experiencing an EGFR GCN increase of at least 1.0 (19.5%; 15/77) were treated with anti-EGFR antibodies before obtaining the sample from the recurrent tumor. The association between anti-EGFR treatment and a GCN decrease of at least 1.0 did not reach statistical significance in the whole study population but became significant when including only patients with distant metastases in the analysis. This finding may be related to the overall accumulation of molecular changes being one of the mechanisms underlying the acquirement of metastatic capability of cancer cells [18] . Particularly, local CRC recurrences have been shown to be genetically more similar to the primary tumor than the distant metastases [19] .
In addition, the proportion of tumors with EGFR GCN b 4.0 increased significantly between the primary and recurrent tumors among the anti-EGFR-treated patients but not among patients receiving other treatment regimens. This change is interesting because it has been shown that EGFR GCN ≥ 4.0 in the primary tumor is associated with a favorable anti-EGFR antibody treatment response in metastatic disease [8] [9] [10] . Notably, none of the patients with tumor pairs showing EGFR GCN increase from less than 4.0 to at least 4.0 (14.3%; 11/77) received anti-EGFR antibodies before the sample was obtained from the recurrent tumor.
Our results show that KRAS wild-type primary tumors have higher EGFR GCN than KRAS-mutated tumors, which is in line with a previous report [20] . This is of interest because both (K)RAS wild-type status [2] and high EGFR GCN [8] [9] [10] 13, 21] are indicators of a beneficial response to EGFR-targeting antibodies in metastatic CRC. The RAS-RAF-MAPK signaling pathway is known to be constantly active in RAS-mutated tumors, which contributes to resistance to anti-EGFR therapies [1] . The specific mechanism by which high EGFR GCN is associated with a favorable treatment response is still unknown. However, elevated EGFR GCN is observed to be related to Chr7 polysomy, and true gene amplifications are rare in CRC [8] .
In our study, the number of patients treated with anti-EGFR therapy was too small for statistical analyses regarding the clinical response. Nevertheless, the patients who had a partial response to anti-EGFR therapy (8/13) had a mean EGFR GCN change of −2.43, whereas the patients with stable disease (4/13) had a mean GCN change of −0.82 and the 1 patient with progressive disease had a stable EGFR GCN.
It is possible that a selection pressure during the antibody treatment leads to the survival of cancer cells with smaller GCNs. Thus, it would be interesting to explore in a larger study population if a true correlation exists between EGFR GCN decrease and a favorable clinical treatment response from anti-EGFR antibodies. However, the study of tissue samples could be complicated by tumor heterogeneity, which is also known to affect EGFR GCN [9] . Few studies have been carried out investigating the EGFR GCN in metastatic tumors in relation to treatment response, but the number of patients has been too small to yield significant information [17] .
Acquired resistance to anti-EGFR therapies is known to occur in a substantial proportion of patients, and several studies have been conducted to elucidate the mechanisms involved in this process [22] [23] [24] [25] [26] . It has been proposed that the antibody treatment functions as a selective pressure, which leads to the survival of those subclones that have genetic properties protecting them against the antibody [24] . Gene amplifications of other receptor tyrosine kinase genes such as HER2 and MET have been noticed in patients who have acquired resistance to anti-EGFR antibodies. In addition, KRAS gene mutations and amplification as well as NRAS and BRAF mutations have been observed to associate with acquired antibody resistance [27] [28] [29] . Possible effects of EGFR GCN changes on acquired resistance have so far not been reported. However, it can be hypothesized that anti-EGFR antibody treatment could result in loss of EGFR polysomy in cancer cells and thereby contribute to acquired resistance.
In this study, lymph node-positive (stage III) tumors showed higher EGFR GCN than did lymph node-negative (stage I-II) tumors. Thus, increased EGFR GCN might denote the adenocarcinomas with higher invasive potential, which is in accordance with the known functions of EGFR signaling [1] .
Although EGFR GCN was not found to be prognostic or predictive for overall survival in this study population (data not shown), its predictive value has been proven in other studies [8] [9] [10] 13, 21] . The present study was designed to compare EGFR GCN change between primary and recurrent disease, and our study material differs from the abovementioned studies in some respects. In our study, the treatment for patients after recurrent disease was heterogeneous and only 30.0% of the patients were treated with EGFR-targeting antibodies. Among them, only 14 patients received anti-EGFR antibody treatment before obtaining the sample from the recurrent tumor. Our study material also included local recurrences (26.3%) in addition to distant metastases.
To conclude, this study suggests that anti-EGFR antibody treatment is associated with EGFR GCN decrease between the primary and corresponding recurrent colorectal adenocarcinomas, whereas no EGFR GCN change is observed in patients receiving other forms of treatment after primary surgery. These results warrant further investigation into a potential connection between EGFR GCN alterations and the evolution of clinical response during anti-EGFR treatment in advancing colorectal adenocarcinoma.
